Skip to Content

Retifanlimab-dlwr (Zynyz) in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC)

Download PQI pdf

Last Updated: October 21, 2026

By: Jeanine Ksar, PharmD, BCOP

About this PQI

The purpose of this PQI is to review clinical considerations and general management of retifanlimab-dlwr in combination with chemotherapy for squamous cell carcinoma of the anal canal (SCAC)

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI